HOME >> BIOLOGY >> NEWS
Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkin's Lymphoma announced by IDEC Pharmaceuticals

Final results of the two ZEVALIN pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals at 42nd annual Society of Hematology meeting -- Three Additional Studies of ZEVALIN Also Presented

SAN FRANCISCO, CALIFORNIA -- Dec. 5, 2000 -- IDEC Pharmaceuticals Corporation (Nasdaq:IDPH) announced the final results of two pivotal trials of ZEVALIN (Ibritumomab Tiuxetan), an investigational radioimmunotherapy, during oral presentations at the 42nd Annual Meeting of the American Society of Hematology (ASH).

Thomas E. Witzig, M.D. of the Mayo Clinic, Rochester, MN, today delivered an oral presentation of a Phase III randomized, controlled study of 143 patients with relapsed or refractory low grade, follicular, or CD20-positive transformed B-cell Non-Hodgkins Lymphoma (NHL). He noted that the ZEVALIN combined with Rituxan arm of the study showed an overall response rate (ORR) of 80 percent, compared to the Rituxan (Rituxumab) alone control arm, which showed an overall response rate of 56 percent. A treatment course for ZEVALIN includes a Rituxan infusion (250 mg/m.2) on day one, followed by infusions of Rituxan (250 mg/m2) and ZEVALIN (at a standard radiation dose of 0.4 mCi/kg of patient body weight) on day eight. A treatment course of the Rituxan control consisted of four weekly doses of 375 mg/m2 of Rituxan.

Dr. Witzig said that 30 percent of the ZEVALIN patients achieved complete responses to therapy. Sixteen percent of Rituxan patients achieved complete responses. To date duration of response estimates between ZEVALIN plus Rituxan and Rituxan alone are not statistically different but further analysis will be conducted as data matures.

ZEVALIN associated toxicity was primarily hematologic, transient and reversible. Thirty-two percent of patients in the ZEVALIN arm of the study experienced Grade 4 neutropenia (neutrophil count below 500/mm3) and five percent experienced Grade 4 thrombocytope
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
4-Dec-2000


Page: 1 2 3 4

Related biology news :

1. Final Alert: 16th EORTC NCI AACR Symposium
2. Final media advisory for the 4th European Breast Cancer Conference (EBCC-4)
3. Final of the 2003/04 Research Councils Business Plan Competition
4. L.A.Times Book Prize Finalist: Book On Evolution Of Bird Flight
5. Could A Nasal Vaccine Finally Get Rid Of The Black Death?
6. Last Comment Sought On Agents Proposed For Report On Carcinogens; A Final ForData On Saccharin, And A Re-Review Of Dioxin Announced
7. Warren Pharmaceuticals publishes results of preclinical evaluation
8. U of T microbiologists achieve results with pattern recognition software
9. Loss of circadian genes results in epilepsy
10. VIB presents its annual results at BIO2004 in San Francisco
11. Scientists discover why not enough choline results in fewer brain cells, poorer memory

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2018)... (PRWEB) , ... July 31, 2018 , ... GSL ... connect seamlessly with LabArchives , the leading cloud-based Electronic Lab Notebook (ELN) platform. ... LabArchives enables researchers to store all of their research data records in a secure, ...
(Date:7/28/2018)... ... 2018 , ... Inthirani Arul, an evidence-based healer, today announces research results based ... autoimmune disorders. , Biomarkers for immune function, blood, as well as, inflammation, were ... 110% increase in overall immunity as seen by the rise in antibody levels , ...
(Date:7/26/2018)... ... , ... The Conference Forum has confirmed the agenda for the 5th Annual ... the Marriott Copley Place in Boston, MA. , Daniel Karlin, MD, Head of Experimental ... to lead the discussion on how and when to implement mobile/digital technology in clinical ...
Breaking Biology News(10 mins):
(Date:7/25/2018)... (PRWEB) , ... July 25, 2018 , ... ... a biofield energy treated proprietary nutraceutical to combat inflammation and autoimmune disorders. ... as, immune function response. The following data was reported:, ...
(Date:7/24/2018)... ... 2018 , ... Mark Stutheit, an evidence-based energy healer, today ... improve anti-inflammatory, and immune function responses. , Biomarkers for systemic and organ-specific inflammation, ... reduced. Results are as follows:, , More than 40% ...
(Date:7/22/2018)... ... July 19, 2018 , ... Mitotech S.A, ... Essex Bio-Investment for Phase 3 clinical program in Dry Eye Disease. Under the ... with approximately $17m allocated towards the first Phase 3 study starting as early ...
(Date:10/12/2017)... ... October 12, 2017 , ... They call it ... biological network, a depiction of a system of linkages and connections so complex ... associate professor of computer science at Worcester Polytechnic Institute (WPI) and director of ...
Breaking Biology Technology:
Cached News: